EX-10.1 3 d531832dex101.htm EX-10.1 ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(B)(4) and 230.406 LICENCE AGREEMENT AS AMENDED ON 28 MARCH 2018License Agreement • May 5th, 2020 • England
Contract Type FiledMay 5th, 2020 JurisdictionCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH
LICENCE AGREEMENT AS AMENDED ON 28 MARCH 2018License Agreement • May 10th, 2018 • Autolus Therapeutics LTD • Biological products, (no disgnostic substances) • England
Contract Type FiledMay 10th, 2018 Company Industry JurisdictionTHIS AGREEMENT was made as of 25 September 2014 (the “Effective Date”), was amended as of 2 March 2016 (the “Amendment Date”), and is amended and restated as of 28 March 2018 (the “Second Amendment Date”)
LICENCE AGREEMENT AS AMENDED ON 28 MARCH 2018License Agreement • May 7th, 2018 • Autolus Therapeutics LTD • Biological products, (no disgnostic substances) • England
Contract Type FiledMay 7th, 2018 Company Industry JurisdictionTHIS AGREEMENT was made as of 25 September 2014 (the “Effective Date”), was amended as of 2 March 2016 (the “Amendment Date”), and is amended and restated as of 28 March 2018 (the “Second Amendment Date”)